Premium
MicroRNAs as potential therapeutic targets to predict responses to oxaliplatin in colorectal cancer: From basic evidence to therapeutic implication
Author(s) -
Moradi Marjaneh Reyhaneh,
Khazaei Majid,
Ferns Gordon A.,
Avan Amir,
AghaeeBakhtiari Seyed Hamid
Publication year - 2019
Publication title -
iubmb life
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.132
H-Index - 113
eISSN - 1521-6551
pISSN - 1521-6543
DOI - 10.1002/iub.2108
Subject(s) - oxaliplatin , microrna , colorectal cancer , wnt signaling pathway , carcinogenesis , cancer research , pi3k/akt/mtor pathway , medicine , biomarker , cancer , oncology , bioinformatics , biology , signal transduction , gene , genetics
Colorectal cancer (CRC) is one of the most common malignancies with poor prognosis. Oxaliplatin‐based chemotherapy is an important treatment for CRC; however, the cells develop resistance to therapy. The mechanisms underlying oxaliplatin resistance are complex and unclear. There is increasing evidence that microRNAs (miRNAs) (i.e., miR‐34a, miR‐143, miR‐153, miR‐27a, miR‐218, and miR‐520) play an essential role in tumorigenesis and chemotherapy resistance, by targeting various cellular and molecular pathways (i.e., PI3K/Akt/Wnt, EMT, p53, p21, and ATM) that are involved in the pathogenesis of CRC. Identifying the miRNAs that are involved in chemo‐resistance, and their function, may help as a potential therapeutic option for treatment of CRC or as potential prognostic biomarker. Here, we summarized the clinical impact of miRNAs that have critical roles in the development of resistance to oxaliplatin in CRC.